Analyst Ratings For NASDAQ:AVXL – Anavex Life Sciences (NASDAQ:AVXL)
.
Some recent analyst ratings include
- 5/16/2018-Maxim Group initiated coverage with a Buy rating.
- 3/8/2018-Roth Capital initiated coverage with a Buy ➝ Buy rating.
- 10/5/2016-FBR & Co Reiterated Rating of Outperform.
Recent Insider Trading Activity For NASDAQ:AVXL – Anavex Life Sciences (NASDAQ:AVXL)
NASDAQ:AVXL – Anavex Life Sciences (NASDAQ:AVXL) has insider ownership of 12.10% and institutional ownership of 22.71%.
- On 3/7/2018 Christopher U Missling, Insider, bought 1,360 with an average share price of $2.92 per share and the total transaction amounting to $3,971.20.
- On 3/5/2018 Christopher U Missling, CEO, bought 1,500 with an average share price of $2.63 per share and the total transaction amounting to $3,945.00.
- On 3/2/2018 Christopher U Missling, CEO, bought 1,650 with an average share price of $2.41 per share and the total transaction amounting to $3,976.50.
- On 10/24/2017 Christopher U Missling, CEO, bought 375 with an average share price of $4.92 per share and the total transaction amounting to $1,845.00.
- On 10/19/2017 Christopher U Missling, Insider, bought 375 with an average share price of $4.49 per share and the total transaction amounting to $1,683.75.
- On 10/17/2017 Christopher U Missling, Insider, bought 375 with an average share price of $4.27 per share and the total transaction amounting to $1,601.25.
- On 10/13/2017 Christopher U Missling, Insider, bought 750 with an average share price of $4.22 per share and the total transaction amounting to $3,165.00.
Recent Trading Activity for NASDAQ:AVXL – Anavex Life Sciences (NASDAQ:AVXL)
Shares of NASDAQ:AVXL – Anavex Life Sciences closed the previous trading session at 2.42 up +0.12 5.00% with shares trading hands.